Abpro Holdings, Inc. (ABPO)
OTCMKTS · Delayed Price · Currency is USD
0.2299
+0.0099 (4.50%)
At close: May 26, 2026
Abpro Holdings Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
3
Market Cap
1.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 183.00K | 61.00K | 50.00% |
| Dec 31, 2023 | 122.00K | -1.91M | -93.99% |
| Dec 31, 2022 | 2.03M | 1.55M | 322.71% |
| Dec 31, 2021 | 480.00K | -1.72M | -78.19% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAbpro Holdings News
- 7 days ago - Abpro Holdings Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Abpro Holdings Annual report: Q4 2025 - Filings
- 4 months ago - Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 months ago - Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 - GlobeNewsWire
- 5 months ago - Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers - GlobeNewsWire
- 6 months ago - Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives - GlobeNewsWire
- 6 months ago - Abpro Holdings Registration statement: Registration Filing - Filings
- 7 months ago - Abpro Holdings Registration statement: Registration Filing - Filings